News in Brief
Abzena remodels ADC facility in Pennsylvania
The $5m (€4m) investment at the firm’s site in Bristol, Pennsylvania – added when Abzena acquired The Chemistry Research Solution in 2015 – was announced last year, and this week the firm said facility remodelling for the GMP manufacturing suite has been completed.
Empty space in the building is set to provide capacity for antibody-drug conjugation (ADC) services, and will allow Abzena to expand its process chemistry capabilities, including HPAPI process chemistry.
The remodelling was carried out by local contractors in Bristol, an Abzena spokesperson told Biopharma-Reporter, and the suite is scheduled for completion around the end of the second quarter of 2018.
We were told: “The facility is equipped with Sartorius Levmixer, FlexAct & AlphaPlus and GE Akta single-use process equipment.”
